All In Biotech

Drug Trial Radar · NCT05388825

Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction

A Randomized, Double-blind, Placebo-controlled, Two-cohort, Three-way Crossover Clinical Trial to Evaluate the Pharmacodynamic Effect of Different Doses of TPN171H Tablets in Mild to Moderate Male Erectile Dysfunction

Last checked: Nov 20, 2026Latest source record: Feb 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Aug 1, 2022

Primary completion

Jan 4, 2023

Study completion Feb 17, 2023

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
May 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled, two-cohort, three-cycle crossover (at least a 5-day cleaning period per cycle), and a multicenter clinical trial design.

Conditions

  • Erectile Dysfunction

Interventions

  • TPN171H 2.5mgDrug

    TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)

  • TPN171H 5mgDrug

    TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)

  • TPN171H 10mgDrug

    TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)

  • Placebo 5mgDrug

    Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)

  • Placebo 10mgDrug

    Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of penile erections of greater than or equal to 60% rigidity as assessed by penile plethysmography (RigiScan PlusTM).Time frame: Baseline and during audiovisual sexual stimulation(60minutes)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Henan Provincial People's Hospital

    Zhenzhou, Henan, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Hospital of Jilin University

    Changchun, Jinlin, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.